Host-directed therapies for bacterial and viral infections

Nature Reviews Drug Discovery

Volumn 17, Issue 1, 2018, Pages 35-56

  Kaufmann, Stefan H E ^a   Dorhoi, Anca ^a,b   Hotchkiss, Richard S ^c   Bartenschlager, Ralf ^d,e,f  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Heidelberg   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CARBAMAZEPINE; CONSENSUS INTERFERON; CYCLOPHILIN A; CYCLOSPORIN A; FLUOXETINE; GEFITINIB; IMATINIB; IMIQUIMOD; ISONIAZID; MARAVIROC; METFORMIN; MICRORNA 122; MYRCLUDEX B; ORPHAN DRUG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PYRAZINAMIDE; RAPAMYCIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIFAMPICIN; SIMVASTATIN; TEMAVIRSEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ANTIINFECTIVE AGENT;

ANTI-INFECTIVE THERAPY; ANTIBIOTIC THERAPY; AUTOIMMUNE DISEASE; AUTOPHAGY; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CONDYLOMA ACUMINATUM; DELTA AGENT HEPATITIS; DEPRESSION; FATIGUE; FEVER; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOST CELL; HOST DIRECTED THERAPY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INNATE IMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SUSTAINED VIROLOGIC RESPONSE; TUBERCULOSIS; VIRUS INFECTION; VIRUS REPLICATION; DRUG EFFECT; DRUG RESEARCH; DRUG RESISTANCE; IMMUNOLOGY;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE; HOST-PATHOGEN INTERACTIONS; HUMANS; PHARMACEUTICAL RESEARCH; VIRUS DISEASES;

EID: 85039801816     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2017.162     Document Type: Review

References (266)

1. O'Neill, J. Tackling drug-resistance infections globally: final report and recommendations. Review on Antimicrobial Resistance https://amr-review.org/sites/default/files/160525-Final%20paper-with%20cover. pdf (2016).
2. De Clercq, E. & Li, G. D. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695-747 (2016).
3. Andersen, P. & Kaufmann, S. H. Novel vaccination strategies against tuberculosis. Cold Spring Harb. Perspect. Med. 4 a018523 (2014).
4. Escolano, A., Dosenovic, P. & Nussenzweig, M. C. Progress toward active or passive HIV-1 vaccination. J. Exp. Med. 214, 3-16 (2017).
5. Melikyan, G. B. HIV entry: a game of hide-and-fuse? Curr. Opin. Virol. 4, 1-7 (2014).
6. Lopalco, L. CCR5: from natural resistance to a new anti-HIV strategy. Viruses 2, 574-600 (2010).
7. Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67, 1268-1282 (2005).
8. Woollard, S. M. & Kanmogne, G. D. Maraviroc: a review of its use in HIV infection and beyond. Drug Des. Dev. Ther. 9, 5447-5468 (2015).
9. Ni, Y. et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070-1083 (2014).
10. Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1, e00049 (2012).
11. Petersen, J. et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol 26, 335-341 (2008).
12. Lempp, F. A., Ni, Y. & Urban, S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat. Rev. Gastroenterol. Hepatol. 13, 580-589 (2016).
13. Blank, A. et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J. Hepatol. 65, 483-489 (2016).
14. Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J. Hepatol. 65, 490-498 (2016).
15. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-1288 (2003).
16. Kaul, A. et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 5, e1000546 (2009).
17. Yang, F. et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J. Virol. 82, 5269-5278 (2008).
18. Hopkins, S. & Gallay, P. A. The role of immunophilins in viral infection. Biochim. Biophys. Acta 1850, 2103-2110 (2015).
19. Flisiak, R. et al. The cyclophilin inhibitor debio 025 combined with PEG IFN-β 2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49, 1460-1468 (2009).
20. Hopkins, S. et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. 57, 47-54 (2012).
21. Pfefferle, S. et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7, e1002331 (2011).
22. Gamble, T. R. et al. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87, 1285-1294 (1996).
23. Braaten, D. & Luban, J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 20, 1300-1309 (2001).
24. Colgan, J. et al. Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity 21, 189-201 (2004).
25. Jopling, C. L., Yi, M. K., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577-1581 (2005).
26. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
27. van der Ree, M. H. et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral. Res. 111, 53-59 (2014).
28. Hsu, S. H. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122, 2871-2883 (2012).
29. Tsai, W. C. et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884-2897 (2012).
30. van der Ree, M. H. et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet 389, 709-717 (2017).
31. Lugo-Villarino, G. & Neyrolles, O. Manipulation of the mononuclear phagocyte system by Mycobacterium tuberculosis. Cold Spring Harb. Perspect. Med. 4, a018549 (2014).
32. Levine, B., Mizushima, N. & Virgin, H. W. Autophagy in immunity and inflammation. Nature 469, 323-335 (2011).
33. Gutierrez, M. G. et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119, 753-766 (2004).
34. Shui, W. Q. et al. Organelle membrane proteomics reveals differential influence of mycobacterial lipoglycans on macrophage phagosome maturation and autophagosome accumulation. J. Proteome Res. 10, 339-348 (2011).
35. Romagnoli, A. et al. ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells. Autophagy 8, 1357-1370 (2012).
36. Zhang, L. et al. Effects of mycobacterium tuberculosis ESAT-6/CFP-10 fusion protein on the autophagy function of mouse macrophages. DNA Cell. Biol. 31, 171-179 (2012).
37. Ganaie, A. A., Lella, R. K., Solanki, R. & Sharma, C. Thermostable hexameric form of eis (Rv2416c) protein of M. tuberculosis plays an important role for enhanced intracellular survival within macrophages. PLoS ONE 6, e27590 (2011).
38. Shin, D. M. et al. Mycobacterium tuberculosis eis regulates autophagy, inflammation, and cell death through redox-dependent signaling. PLoS Pathog. 6, e1001230 (2010).
39. Gurk-Turner, C., Manitpisitkul, W. & Cooper, M. A. Comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 94, 659-668 (2012).
40. Floto, R. A. et al. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages. Autophagy 3, 620-622 (2007).
41. Coriat, R. et al. Reactivation of tuberculosis during temsirolimus therapy. Invest. New Drugs 29, 1494-1496 (2011).
42. Fijalkowska-Morawska, J. B., Jagodzinska, M. & Nowicki, M. Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient. Ann. Transplant. 16, 107-110 (2011).
43. Schiebler, M. et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol. Med. 7, 127-139 (2015).
44. Stanley, S. A. et al. Identification of host-targeted small molecules that restrict intracellular mycobacterium tuberculosis growth. PLoS Pathog. 10, e1003946 (2014).
45. Gupta, S. et al. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am. J. Respir. Crit. Care Med. 188, 600-607 (2013).
46. Gupta, S., Tyagi, S. & Bishai, W. R. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob. Agents Chemother. 59, 673-676 (2015).
47. Singhal, A. et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 6, 263ra159 (2014).
48. Wallis, R. S. & Hafner, R. Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 15, 255-263 (2015).
49. Bruns, H. et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 189, 4069-4078 (2012).
50. Napier, R. J. et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10, 475-485 (2011).
51. Pandey, A. K. & Sassetti, C. M. Mycobacterial persistance requires the utilization of host cholesterol. Proc. Natl Acad. Sci. USA 105, 4376-4380 (2008).
52. Lobato, L. S. et al. Statins increase rifampin mycobactericidal effect. Antimicrob. Agents Chemother. 58, 5766-5774 (2014).
53. Parihar, S. P. et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J. Infect. Dis. 209, 754-763 (2014).
54. Heim, M. H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 13, 535-542 (2013).
55. Dutta, N. K. et al. Statin adjunctive therapy shortens the duration of TB treatment in mice. J. Antimicrob. Chemother. 71, 1570-1577 (2016).
56. Lai, C. C. et al. Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort. Thorax 71, 646-651 (2016).
57. Thomas, E., Ghany, M. G. & Liang, T. J. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir. Chem. Chemother. 23, 1-12 (2012).
58. Pawlotsky, J. M. in Hepatitis C Virus: From Molecular Virology to Antiviral Therapy (ed. Bartenschlager, R.) 321-342 (Springer, 2013).
59. Sheahan, T. et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15, 190-202 (2014).
60. Wack, A., Terczynska-Dyla, E. & Hartmann, R. Guarding the frontiers: the biology of type III interferons. Nat. Immunol. 16, 802-809 (2015).
61. Muir, A. J. et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 61, 1238-1246 (2014).
62. Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63, 261-283 (2016).
63. World Health Organization. Guidelines approved by the guidelines review committee. In: Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. (www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/) (WHO, 2015).
64. Marcellin, P. et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150, 134-144.e110 (2016).
65. Petersen, J., Thompson, A. J. & Levrero, M. Aiming for cure in HBV and HDV infection. J. Hepatol. 65, 835-848 (2016).
66. de Niet, A. et al. Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy. J. Hepatol. 64, 539-546 (2016).
67. Miailhes, P. et al. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. J. Hepatol. 61, 761-769 (2014).
68. Poli, G., Orenstein, J. M., Kinter, A., Folks, T. M. & Fauci, A. S. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244, 575-577 (1989).
69. Doyle, T., Goujon, C. & Malim, M. H. HIV-1 and interferons: whO's interfering with whom? Nat. Rev. Microbiol. 13, 403-413 (2015).
70. Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601-605 (2014).
71. Asmuth, D. M. et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J. Infect. Dis. 201, 1686-1696 (2010).
72. Bilu, D. & Sauder, D. N. Imiquimod: modes of action. Br. J. Dermatol. 149 (Suppl. 66), 5-8 (2003).
73. Hayden, F. G. in The Pharmacological Basis of Therapeutics (eds Brunton, L. L., Lazo, J. S. & Parker, K.) 1225-1242 (Macmillan, 2006).
74. Miao, X. et al. Potential efficacy of imiquimod on immunity-related cytokines in murine skin in vivo and in human Langerhans cells in vitro. Int. J. Dermatol. 51, 1116-1122 (2012).
75. Karnes, J. B. & Usatine, R. P. Management of external genital warts. Am. Fam. Physician 90, 312-318 (2014).
76. Cillo, A. R. & Mellors, J. W. Which therapeutic strategy will achieve a cure for HIV-1? Curr. Opin. Virol. 18, 14-19 (2016).
77. Li, P. et al. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat. Med. 22, 807-811 (2016).
78. Hutter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698 (2009).
79. Zhen, A. & Kitchen, S. Stem-cell-based gene therapy for HIV infection. Viruses 6, 1-12 (2013).
80. Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385 (2015).
81. Riley, J. L. & Montaner, L. J. Cell-mediated immunity to target the persistent human immunodeficiency virus reservoir. J. Infect. Dis. 215, S160-s171 (2017).
82. Tzeng, H. T. et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS ONE 7, e39179 (2012).
83. Fuller, M. J. et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc. Natl Acad. Sci. USA 110, 15001-15006 (2013).
84. Velu, V. et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206-210 (2009).
85. Crowle, A. J., Ross, E. J. & May, M. H. Inhibition by 1,25(oh)2-vitamin-d3 of the multiplication of virulent tubercle-bacilli in cultured human macrophages. Infect. Immun. 55, 2945-2950 (1987).
86. Rook, G. A. W. et al. Vitamin-D3, gamma-interferon, and control of proliferation of mycobacterium-tuberculosis by human-monocytes. Immunology 57, 159-163 (1986).
87. Liu, P. T., Stenger, S., Tang, D. H. & Modlin, R. L. Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 179, 2060-2063 (2007).
88. O'Connor, G. et al. Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv. Drug Deliv. Rev. 102, 33-54 (2016).
89. Coussens, A. K., Wilkinson, R. J. & Martineau, A. R. Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3. PLoS Pathog. 11, e1005007 (2015).
90. Mily, A. et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: A randomized controlled trial. PLoS ONE 10, e0138340 (2015).
91. Daley, P. et al. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis 15, 528-534 (2015).
92. Martineau, A. R. et al. High-dose vitamin D-3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377, 242-250 (2011).
93. Salahuddin, N. et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT study supplementary cholecalciferol in recovery from tuberculosis. a randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect. Dis. 13, 22 (2013).
94. Tukvadze, N. et al. High-dose vitamin D-3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial. Am. J. Clin. Nutr. 102, 1059-1069 (2015).
95. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02968927 (2016).
96. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03011580 (2016).
97. Crowle, A. J. & Ross, E. J. Inhibition by retinoic acid of multiplication of virulent tubercle-bacilli in cultured human macrophages. Infect. Immun. 57, 840-844 (1989).
98. Greenstein, R. J., Su, L. Y. & Brown, S. T. Vitamins A and D inhibit the growth of mycobacteria in radiometric culture. PLoS ONE 7, e29631 (2012).
99. Greenstein, R. J. et al. Unanticipated Mycobacterium tuberculosis complex culture inhibition by immune modulators, immune suppressants, a growth enhancer, and vitamins A and D: clinical implications. Int. J. Infect. Dis. 26, 37-43 (2014).
100. Wheelwright, M. et al. All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2. J. Immunol. 192, 2280-2290 (2014).
101. Knaul, J. K. et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 190, 1053-1066 (2014).
102. Yamada, H., Mizuno, S., Ross, A. C. & Sugawara, I. Retinoic acid therapy attenuates the severity of tuberculosis while altering lymphocyte and macrophage numbers and cytokine expression in rats infected with Mycobacterium tuberculosis. J. Nutr. 137, 2696-2700 (2007).
103. Lawson, L. et al. Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis. Trop. Med. Int. Health 15, 1481-1490 (2010).
104. Visser, M. E. et al. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am. J. Clin. Nutr. 93, 93-100 (2011).
105. Dawson, R. et al. Immunomodulation with recombinant interferon-gamma 1b in pulmonary tuberculosis. PLoS ONE 4, e6984 (2009).
106. Gao, X. F., Yang, Z. W. & Li, J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Infect. Dis. 15, E594-E600 (2011).
107. Condos, R., Rom, W. N. & Schluger, N. W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349, 1513-1515 (1997).
108. Koh, W. J. et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J. Kor. Med. Sci. 19, 167-171 (2004).
109. Suarez-Mendez, R. et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis. 4, 44 (2004).
110. Babudieri, S. et al. Tuberculosis screening before anti-hepatitis C virus therapy in prisons. Emerg. Infect. Dis. 18, 689-691 (2012).
111. Belkahla, N. et al. Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C. Rev. Med. Interne 31, e1-3 (2010).
112. Telesca, C. et al. Interferon treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J. Infect. 54, e223-226 (2007).
113. Giosue, S. et al. Effects of aerosolized interferon in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.158, 1156-1162 (1998).
114. Tsai, M. C., Lin, M. C. & Hung, C. H. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis. J. Formos. Med. Assoc. 108, 746-750 (2009).
115. Zhukova, E. M., Krasnov, V. A., Petrenko, T. I. & Romanov, V. V. [Interferon 2b in the complex therapy of patients with pulmonary tuberculosis concurrent with bronchoobstructive syndrome]. Tuberk. Biolezni Legkih 12, 58-61 (2009).
116. Boomer, J. S. et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306, 2594-2605 (2011).
117. Chang, K. et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit. Care 18, R3 (2014).
118. Guignant, C. et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit. Care 15, R99 (2011).
119. Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273-290 (2016).
120. Hassan, S. S., Akram, M., King, E. C., Dockrell, H. M. & Cliff, J. M. PD-1, PD-L1 and PD-L2 gene expression on T-Cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS ONE 10, e0137646 (2015).
121. Saharia, K. K. et al. Tuberculosis therapy modifies the cytokine profile, maturation state, and expression of inhibitory molecules on Mycobacterium tuberculosis-specific CD4+ T-cells. PLoS ONE 11, e0158262 (2016).
122. Singh, A., Mohan, A., Dey, A. B. & Mitra, D. K. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon producing T cells from apoptosis in patients with pulmonary tuberculosis. J. Infect. Dis. 208, 603-615 (2013).
123. Jurado, J. O. et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 181, 116-125 (2008).
124. McNab, F. W. et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur. J. Immunol. 41, 1941-1947 (2011).
125. Singh, A., Dey, A. B., Mohan, A. & Mitra, D. K. Programmed death-1 receptor suppresses α-IFN producing NKT cells in human tuberculosis. Tuberculosis (Edinb.) 94, 197-206 (2014).
126. Garcia Jacobo, R. E. et al. Analysis of Th1, Th17 and regulatory T cells in tuberculosis case contacts. Cell. Immunol. 289, 167-173 (2014).
127. Li, N. et al. Enrichment of regulatory T-cells in blood of patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.19, 1230-1238 (2015).
128. Phillips, B. L. et al. LAG3 expression in active Mycobacterium tuberculosis infections. Am. J. Pathol. 185, 820-833 (2015).
129. Sada-Ovalle, I. et al. The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis. J. Immunol. 189, 5896-5902 (2012).
130. Sada-Ovalle, I. et al. Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients. J. Int. AIDS Soc. 18, 20078 (2015).
131. Jayaraman, P. et al. TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection. PLoS Pathog. 12, e1005490 (2016).
132. Sakai, S. et al. CD4 T cell-derived IFN-α plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 12, e1005667 (2016).
133. Lee, J. J., Chan, A. & Tang, T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. Acta Oncol. 55, 519-520 (2016).
134. Beamer, G., Major, S., Das, B. & Campos-Neto, A. Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment. Am. J. Pathol. 184, 3170-3175 (2014).
135. Das, B. et al. CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci. Transl Med. 5, 170ra113 (2013).
136. Garhyan, J. et al. Preclinical and clinical evidence of Mycobacterium tuberculosis persistence in the hypoxic niche of bone marrow mesenchymal stem cells after therapy. Am. J. Pathol. 185, 1924-1934 (2015).
137. Skrahin, A. et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir. Med. 2, 108-122 (2014).
138. Skrahin, A. et al. Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis. J. Clin. Tuberc. Other Mycobact. Dis. 4, 21-27 (2016).
139. Zumla, A. et al. Inflammation and tuberculosis: host-directed therapies. J. Intern. Med. 277, 373-387 (2015).
140. Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003).
141. Hotchkiss, R. S., Monneret, G. & Payen, D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13, 260-268 (2013).
142. Docke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-α treatment. Nat. Med. 3, 678-681 (1997).
143. Rosenbloom, A. J. et al. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 127, 2139-2150 (2005).
144. Presneill, J. J., Harris, T., Stewart, A. G., Cade, J. F. & Wilson, J. W. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 166 (2002).
145. Wasserman, D., Ioannovich, J. D., Hinzmann, R. D., Deichsel, G. & Steinmann, G. G. Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit. Care Med. 26, 434-439 (1998).
146. Delsing, C. E. et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect. Dis. 14, 166 (2014).
147. Meisel, C. et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180, 640-648 (2009).
148. Hall, M. W. et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37, 525-532 (2011).
149. Dries, D. J. et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch. Surg. 129, 1031-1041 (1994).
150. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02361528 (2015).
151. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01649921 (2014).
152. Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11, 330-342 (2011).
153. Sereti, I. et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 10, e1003890 (2014).
154. Venet, F. et al. IL-7 restores lymphocyte functions in septic patients. J. Immunol. 189, 5073-5081 (2012).
155. Unsinger, J. et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 184, 3768-3779 (2010).
156. Alstadhaug, K. B. et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol. 71, 1030-1035 (2014).
157. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02960854 (2016).
158. Hotchkiss, R. S. & Moldawer, L. L. Parallels between cancer and infectious disease. N. Engl. J. Med. 371, 380-383 (2014).
159. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02576457 (2015).
160. Wu, J. et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care 17, R8 (2013).
161. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02867267 (2016).
162. Martina, B. E. Dengue pathogenesis: a disease driven by the host response. Sci. Prog. 97, 197-214 (2014).
163. Modhiran, N. et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci. Transl. Med. 7, 304ra142 (2015).
164. Chen, H. R. et al. Dengue virus nonstructural protein 1 induces vascular leakage through macrophage migration inhibitory factor and autophagy. PLoS Negl. Trop. Dis 10, e0004828 (2016).
165. Puerta-Guardo, H., Glasner, D. R. & Harris, E. Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability. PLoS Pathog. 12, e1005738 (2016).
166. Nguyen, T. H. et al. Corticosteroids for dengue-why don't they work? PLoS Negl. Trop. Dis 7, e2592 (2013).
167. Tam, D. T. et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin. Infect. Dis. 55, 1216-1224 (2012).
168. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008).
169. Nhu, Q. M. et al. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal. Immunol 3, 29-39 (2010).
170. Shirey, K. A. et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497, 498-502 (2013).
171. Walsh, K. B. et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl Acad. Sci. USA 108, 12018-12023 (2011).
172. Zheng, B. J. et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl Acad. Sci. USA 105, 8091-8096 (2008).
173. Brassard, P. et al. The effect of statins on influenza-like illness morbidity and mortality. Pharmacoepidemiol. Drug Saf. 26, 63-70 (2016).
174. Frost, F. J., Petersen, H., Tollestrup, K. & Skipper, B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131, 1006-1012 (2007).
175. Laidler, M. R. et al. Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations. Open Forum Infect. Dis. 2, ofv028 (2015).
176. Vandermeer, M. L. et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J. Infect. Dis. 205, 13-19 (2012).
177. Viasus, D. et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J. Infect. 62, 193-199 (2011).
178. Aldridge, J. R. Jr. et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl Acad. Sci. USA 106, 5306-5311 (2009).
179. Budd, A. et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents Chemother. 51, 2965-2968 (2007).
180. Moseley, C. E., Webster, R. G. & Aldridge, J. R. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir. Viruses 4, 307-311 (2010).
181. Sakai, S. et al. Therapeutic effect of anti-macrophage inflammatory protein 2 antibody on influenza virus-induced pneumonia in mice. J. Virol. 74, 2472-2476 (2000).
182. Miller, B. E. et al. The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur. J. Drug Metab. Pharmacokinet. 39, 173-181 (2014).
183. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02927431 (2016).
184. Dorhoi, A. & Kaufmann, S. H. E. Perspectives on host adaptation in response to Mycobacterium tuberculosis: modulation of inflammation. Sem. Immunol. 26, 533-542 (2014).
185. Lenaerts, A., Barry 3rd, C. E. & Dartois, V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol. Rev. 264, 288-230 (2015).
186. Marakalala, M. J. et al. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat. Med. 22, 531-538 (2016).
187. Gumbo, T., Lenaerts, A. J., Hanna, D., Romero, K. & Nuermberger, E. Nonclinical models for antituberculosis drug development: a landscape analysis. J. Infect. Dis. 211 (Suppl. 3), S83-S95 (2015).
188. Divangahi, M., Behar, S. M. & Remold, H. in New Paradigm of Immunity to Tuberculosis (ed. Divangahi, M.) 103-120 (Springer, 2013).
189. Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99-103 (2014).
190. Fujiwara, H., Kleinhenz, M. E., Wallis, R. S. & Ellner, J. J. Increased interleukin-1 production and monocyte suppressor-cell activity associated with human tuberculosis. Am. Rev. Respir. Dis. 133, 73-77 (1986).
191. Katti, M. K. Assessment of serum IL-1, IL-2 and IFN-α levels in untreated pulmonary tuberculosis patients: role in pathogenesis. Arch. Med. Res. 42, 199-201 (2011).
192. Law, K. et al. Increased release of interleukin-1α, interleukin-6, and tumor necrosis factor-α by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.153, 799-804 (1996).
193. Zhang, G. L. et al. Allele-specific induction of IL-1α expression by C/EBP and PU.1 contributes to increased tuberculosis susceptibility. PLoS Pathog. 10 e1004426 (2014).
194. Rangel Moreno, J. et al. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 106, 257-266 (2002).
195. Vilaplana, C. et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199-202 (2013).
196. Byrne, S. T., Denkin, S. M. & Zhang, Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J. Antimicrob. Chemother. 59, 313-316 (2007).
197. Dutta, N. K., Asok Kurnar, K., Mazumdar, K. & Dastidar, S. G. In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium. Indian J. Exp. Biol. 42, 922-927 (2004).
198. Dutta, N. K., Mazumdar, K., Dastidar, S. G. & Park, J. H. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice. Int. J. Antimicrob. Agents 30, 336-340 (2007).
199. Guzman, J. D. et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 3, e002672 (2013).
200. Misra, U. K., Kalita, J. & Nair, P. P. Role of aspirin in tuberculous meningitis: A randomized open label placebo controlled trial. J. Neurol. Sci. 293, 12-17 (2010).
201. Schoeman, J. F., van Rensburg, A. J., Laubscher, J. A. & Springer, P. The role of aspirin in childhood tuberculous meningitis. J. Child Neurol. 26, 956-962 (2011).
202. Wallis, R. S. et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect. Dis. 16, E34-E46 (2016).
203. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02781909 (2016).
204. Dorhoi, A. & Kaufmann, S. H. E. Tumor necrosis factor-α in mycobacterial infection. Semin. Immunol. 26, 203-209 (2014).
205. Roca, F. J. & Ramakrishnan, L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 153, 521-534 (2013).
206. Blackmore, T. K., Manning, L., Taylor, W. J. & Wallis, R. S. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin. Infect. Dis. 47, E83-E85 (2008).
207. Wallis, R. S., van Vuuren, C. & Potgieter, S. Adalimumab treatment of life-threatening tuberculosis. Clin. Infect. Dis. 48, 1429-1432 (2009).
208. Wallis, R. S. et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. Aids 18, 257-264 (2004).
209. Paige, C. & Bishai, W. R. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell. Microbiol. 12, 301-309 (2010).
210. Casarini, M. et al. Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 159, 143-148 (1999).
211. Djoba Siawaya, J. F. et al. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. Cytokine 47, 132-136 (2009).
212. Chowdhury, I. H. et al. Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy. Mol. Immunol. 62, 159-168 (2014).
213. Okada, M. et al. Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice. Clin. Dev. Immunol 2011, 404929 (2011).
214. Winthrop, K. L. et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann. Rheum. Dis. 75, 1133-1138 (2016).
215. Maiga, M. et al. Risk of tuberculosis reactivation with tofacitinib (CP-690550). J. Infect. Dis. 205, 1705-1708 (2012).
216. Maiga, M. et al. Efficacy of adjunctive tofacitinib therapy in mouse models of tuberculosis. EBioMedicine 2, 868-873 (2015).
217. Ahidjo, B. A. & Bishai, W. R. Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis. EBioMedicine 4, 7-8 (2016).
218. Tramontana, J. M. et al. Thalidomide treatment reduces tumor necrosis factor-α production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. 1, 384-397 (1995).
219. Schoeman, J. F. et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J. Child Neurol. 19, 250-257 (2004).
220. Koo, M. S. et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS ONE 6, e17091 (2011).
221. Subbian, S. et al. Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis. Front. Immunol. 7, 238 (2016).
222. Subbian, S. et al. Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model. EBioMedicine 4, 104-114 (2016).
223. Maiga, M. et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J. Infect. Dis. 208, 512-519 (2013).
224. Turner, J., Frank, A. A., Brooks, J. V., Marietta, P. M. & Orme, I. M. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 102, 248-253 (2001).
225. Wallis, R. S. et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J. Infect. Dis. 174, 727-733 (1996).
226. Dooley, D. P., Carpenter, J. L. & Rademacher, S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin. Infect. Dis. 25, 872-887 (1997).
227. Critchley, J. A., Young, F., Orton, L. & Garner, P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 13, 223-237 (2013).
228. Tobin, D. M. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434-446 (2012).
229. Wallis, R. S. Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis. Open Forum Infect. Dis. 1, ofu020 (2014).
230. Mayanja-Kizza, H. et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J. Infect. Dis. 191, 856-865 (2005).
231. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01924286 (2013).
232. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02060006 (2014).
233. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02169882 (2014).
234. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02588196 (2015).
235. Fisher, C. J. Jr. et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The soluble TNF receptor sepsis study group. N. Engl. J. Med. 334, 1697-1702 (1996).
236. Fisher, C. J. Jr. et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22, 12-21 (1994).
237. Shakoory, B. et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 44, 275-281 (2016).
238. Alatas, F. et al. Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest 125, 2156-2159 (2004).
239. Matsuyama, W. et al. Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. Am. J. Respir. Crit. Care 162, 1120-1122 (2000).
240. Polena, H. et al. Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination. Sci. Rep. 6, 33162 (2016).
241. Kumar, N. P., Banurekha, V. V., Nair, D. & Babu, S. Circulating angiogenic factors as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis. PLoS ONE 11, e0146318 (2016).
242. Datta, M. et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc. Natl Acad. Sci. USA 112, 1827-1832 (2015).
243. Oehlers, S. H. et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature 517, 612-615 (2015).
244. Lin, C. C., Wang, J. Y. & Pu, Y. S. Active tuberculosis during temsirolimus and bevacizumab treatment. J. Clin. Oncol 31, E18-E20 (2013).
245. Zheng, X. W. et al. Subcutaneous tuberculosis formation during FOLFIRI and bevacizumab treatment: a case report. Int. J. Colorectal. Dis. 31, 943-944 (2016).
246. Oehlers, S. H. et al. Infection-induced vascular permeability aids mycobacterial growth. J. Infect. Dis. 215, 813-817 (2016).
247. Via, L. E. et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76, 2333-2340 (2008).
248. Eldholm, V. et al. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol. 15, 490 (2014).
249. Gengenbacher, M. & Kaufmann, S. H. E. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol. Rev. 36, 514-532 (2012).
250. Moreno-Gamez, S. et al. Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance. Proc. Natl Acad. Sci. USA 112, E2874-E2883 (2015).
251. Shi, L. B., Eugenin, E. A. & Subbian, S. Immunometabolism in tuberculosis. Front. Immunol. 7, 150 (2016).
252. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
253. Michelucci, A. et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc. Natl Acad. Sci. USA 110, 7820-7825 (2013).
254. Rachman, H. et al. Critical role of methylglyoxal and AGE in mycobacteria-induced macrophage apoptosis and activation. PLoS ONE 1, e29 (2006).
255. Kubler, A. et al. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation. J. Pathol. 235, 431-444 (2015).
256. Ong, C. W. M., Elkington, P. T. & Friedland, J. S. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 190, 9-18 (2014).
257. Lee, S. H., Han, S. K., Shim, Y. S. & Yim, J. J. Effect of matrix metalloproteinase-9-1562C/T gene polymorphism on manifestations of pulmonary tuberculosis. Tuberculosis (Edinb) 89, 68-70 (2009).
258. Sathyamoorthy, T. et al. Gender-dependent differences in plasma matrix metalloproteinase-8 elevated in pulmonary tuberculosis. PLoS ONE 10, e0117605 (2015).
259. Walker, N. F. et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 185, 989-997 (2012).
260. Dorhoi, A. et al. Reverse translation in tuberculosis: neutrophils provide clues for understanding development of active disease. Front. Immunol. 5, 36 (2014).
261. Irwin, S. M. et al. Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis. Dis. Model. Mech. 8, 591-602 (2015).
262. Lanoix, J. P., Lenaerts, A. J. & Nuermberger, E. L. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis. Model. Mech. 8, 603-610 (2015).
263. Kaplan, G. et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71, 7099-7108 (2003).
264. WHO. Global Tuberculosis Report 2016. World Health Organization http://www.who.int/tb/publications/global-report/en/(2016).
265. Eldholm, V. & Balloux, F. Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol. 24, 637-648 (2016).
266. Bloemberg, G. V., Gagneux, S. & Bottger, E. C. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N. Engl. J. Med. 373, 1986-1988 (2015).